Staphylokinase: A Comprehensive Review of its Thrombolytic Potential, Clinical Development, and Future Prospects

Introduction: The Evolving Landscape of Thrombolytic Therapy

Thrombotic diseases, including acute myocardial infarction (AMI), ischemic stroke, deep vein thrombosis (DVT), and pulmonary embolism (PE), represent a leading cause of mortality and morbidity worldwide, imposing a substantial burden on global health systems.[1] The cornerstone of treatment for these acute conditions is the rapid dissolution of the occlusive thrombus to restore blood flow, a strategy known as thrombolytic therapy. The development of plasminogen activators—agents that convert the zymogen plasminogen into the active fibrin-degrading enzyme plasmin—has revolutionized the management of these life-threatening events.[1]

The field has seen successive generations of thrombolytic agents, from the non-fibrin-specific first-generation drugs like streptokinase and urokinase to the more fibrin-specific second-generation agent, recombinant tissue-type plasminogen activator (t-PA, alteplase).[1] Despite these advances, the ideal thrombolytic agent remains elusive, with existing therapies facing limitations related to bleeding risk, incomplete efficacy, reocclusion, and cost.[3]

In this context, staphylokinase (SAK) emerged as a highly promising third-generation thrombolytic agent.[3] Staphylokinase is a 136-amino acid, non-glycosylated protein secreted by certain lysogenic strains of

Staphylococcus aureus.[6] Unlike direct-acting proteases, SAK is a profibrinolytic agent that exhibits a unique mechanism of plasminogen activation, conferring a high degree of fibrin-specificity that distinguishes it from its predecessors.[11]

This report provides a comprehensive and exhaustive analysis of staphylokinase, tracing its journey from a bacterial virulence factor to a sophisticated, clinically evaluated therapeutic. It will explore the molecular pharmacology that underpins its potent and fibrin-specific activity, critically review the extensive clinical trial data across a range of thrombotic indications, and detail the formidable challenge of immunogenicity that initially hindered its development. Furthermore, this review will chronicle the successful application of rational protein engineering to create non-immunogenic variants that have demonstrated significant clinical promise. Finally, it will examine the bioprocess engineering strategies required for its large-scale production and discuss its current regulatory status and future prospects as a next-generation thrombolytic agent. Staphylokinase represents a paradigmatic case study in modern drug development, illustrating how a deep understanding of molecular mechanisms, coupled with advanced bioengineering, can overcome significant biological barriers to unlock the full therapeutic potential of a promising molecule.

Molecular Profile and Pharmacological Mechanism of Action

A. Structure and Function of Staphylokinase

Staphylokinase is a relatively small, single-chain polypeptide with a molecular weight of approximately 15.5 to 16 kDa, composed of 136 amino acids and lacking disulfide bridges.[5] Structurally, it is a globular protein whose N-terminal region is critical for its biological activity.[15] Unlike direct-acting thrombolytics such as t-PA and urokinase, which are serine proteases, staphylokinase itself possesses no intrinsic enzymatic activity.[6] It functions as an indirect plasminogen activator, or a profibrinolytic agent, whose therapeutic effect is entirely dependent on its interaction with the host's plasminogen system.[11]

B. The Indirect Pathway of Plasminogen Activation

The mechanism by which staphylokinase induces fibrinolysis is a sophisticated, multi-step process that distinguishes it from other plasminogen activators.

1. Complex Formation: The initial step involves the formation of a high-affinity, 1:1 stoichiometric, non-covalent complex with either circulating plasminogen (Plg) or, more efficiently, with the active enzyme plasmin (Pli).[6]
2. Conformational Activation: Upon binding to SAK, the plasminogen molecule undergoes a critical conformational change. This structural rearrangement exposes the active site within the plasminogen moiety, transforming the inert Plg·SAK pro-activator complex into a proteolytically active Pli·SAK activator complex without the need for proteolytic cleavage.[11] This activation step is a key feature of its indirect mechanism.
3. Catalytic Conversion: The newly formed Pli·SAK activator complex then functions as a potent enzyme, efficiently catalyzing the conversion of other, free plasminogen molecules into plasmin. Plasmin is the principal effector enzyme of the fibrinolytic system, responsible for the proteolytic degradation of the fibrin meshwork that forms the structural basis of a thrombus.[1]

C. The Paradigm of Fibrin-Specificity: A Comparative Analysis

The most significant pharmacological advantage of staphylokinase is its remarkable fibrin-specificity, which translates to a lower risk of systemic bleeding complications compared to first-generation agents. This specificity is not derived from a direct affinity for fibrin, but rather from a nuanced interplay with plasma inhibitors.

• Staphylokinase (SAK): The key to SAK's fibrin-specificity lies in its interaction with α2-antiplasmin, the primary physiological inhibitor of plasmin in circulation. In the bloodstream, away from a clot, any Pli·SAK complex that forms is rapidly and irreversibly inhibited by α2-antiplasmin.[11] This prevents widespread, systemic activation of plasminogen and the subsequent degradation of circulating fibrinogen and other clotting factors. However, when the Pli·SAK complex binds to the surface of a fibrin clot, it is sterically protected from inhibition by α2-antiplasmin. This protection allows the activator complex to function efficiently and locally, concentrating its plasminogen-activating effect at the site of the thrombus. This mechanism ensures that fibrinolysis is largely confined to the clot, preserving systemic hemostatic proteins and minimizing bleeding risk.[11] Furthermore, SAK can be recycled from the inactivated plasmin·α2-antiplasmin complex, further enhancing its local efficacy.[11]
• Streptokinase (SK): In stark contrast, streptokinase is a non-fibrin-specific agent. The activator complexes it forms with plasminogen and plasmin are resistant to inhibition by α2-antiplasmin.[17] Consequently, streptokinase activates both fibrin-bound and circulating plasminogen indiscriminately. This leads to systemic plasmin generation, rapid depletion of α2-antiplasmin, and extensive degradation of plasma fibrinogen, Factor V, and Factor VIII, resulting in a systemic lytic state and a significantly higher propensity for hemorrhagic complications.[1]
• Tissue-type Plasminogen Activator (t-PA, Alteplase): t-PA is a direct-acting serine protease with an intrinsic, albeit partial, fibrin-specificity. Its mechanism relies on "surface assembly," where its catalytic efficiency for converting plasminogen to plasmin is markedly enhanced when both molecules are bound to the fibrin surface.[2] This localization increases its effectiveness at the clot. However, at the therapeutic concentrations required for effective thrombolysis, t-PA can still induce significant systemic plasminogen activation and fibrinogen consumption, leading to bleeding risks.[17]

The superior fibrin-sparing profile of staphylokinase, a direct result of its unique inhibitor-regulated mechanism, was the primary driver for its development as a potentially safer and more effective thrombolytic agent. This pharmacological elegance, however, was initially offset by the significant clinical challenge of immunogenicity.

Feature	Staphylokinase (SAK)	Streptokinase (SK)	Alteplase (t-PA)
Class	Bacterial, Indirect Activator	Bacterial, Indirect Activator	Human, Direct Activator
Mechanism of Action	Forms 1:1 complex with plasminogen, which then activates other plasminogen molecules 16	Forms 1:1 complex with plasminogen, which then activates other plasminogen molecules 20	Directly cleaves plasminogen to plasmin 17
Fibrin Specificity	High	Low	Moderate-High
Mechanism of Specificity	Pli·SAK complex is rapidly inhibited by α2-antiplasmin in circulation but protected from inhibition when bound to fibrin 11	SK·Pli complex is resistant to α2-antiplasmin, leading to systemic activation 17	Preferentially activates plasminogen bound to the fibrin surface ("surface assembly") 2
Systemic Fibrinogenolysis	Minimal 11	Extensive 20	Moderate 17
Immunogenicity	High (wild-type) 22; Low (engineered variants) 24	High 25	Low 25
Key Clinical Limitation	Immunogenicity (wild-type); Bleeding risk (though lower than SK)	Immunogenicity; Systemic bleeding; Hypotension	Short half-life; Bleeding risk (including intracranial hemorrhage); High cost

Clinical Efficacy Across Thrombotic Indications

The therapeutic potential of recombinant staphylokinase (rSAK) has been extensively evaluated in clinical trials across the spectrum of thrombotic diseases, from arterial occlusions in AMI and PAO to venous thromboembolism in DVT and PE. These studies have consistently demonstrated its potent thrombolytic efficacy while also defining its safety profile and limitations.

A. Acute Myocardial Infarction (AMI)

Early clinical development of staphylokinase focused heavily on AMI, where it was compared against the then-gold standard, alteplase.

• The STAR Trial: A pivotal randomized trial compared intravenous rSAK (STAR) with accelerated alteplase in 100 patients with AMI. The primary endpoint, coronary artery patency defined as Thrombolysis In Myocardial Infarction (TIMI) grade 3 flow at 90 minutes, was achieved in 62% of STAR patients versus 58% of alteplase patients. This demonstrated that STAR was at least as effective as alteplase for achieving early coronary recanalization.[26] A subsequent study using a double-bolus regimen of rSAK confirmed these findings, achieving a 68% TIMI-3 flow rate compared to 57% with alteplase.[23]
• Fibrin-Specificity in AMI: A key finding from these trials was the profound fibrin-specificity of staphylokinase in a clinical setting. In the STAR trial, residual fibrinogen levels at 90 minutes were 118% of baseline with STAR, indicating virtually no systemic fibrinogen degradation. In contrast, fibrinogen levels dropped to 68% of baseline with alteplase, a statistically significant difference (p<0.0005).[26] This superior fibrin-sparing effect was a consistent finding across studies and confirmed the pharmacological promise of SAK.[23]
• Pegylated Variants (CAPTORS Trials): To facilitate easier administration via a single bolus injection, a pegylated form of SAK (PEG-Sak) was developed and tested in the Collaborative Angiographic Patency Trial of Recombinant Staphylokinase (CAPTORS) I and II trials.[29] The CAPTORS II trial was a dose-finding study that evaluated PEG-Sak against accelerated rt-PA. At the highest dose studied (0.05 mg/kg), PEG-Sak achieved a TIMI 3 flow rate of 41%, which was similar to the 41% rate observed with rt-PA. However, the trial was halted prematurely after three patients receiving PEG-Sak experienced intracranial hemorrhage, highlighting a narrow therapeutic window for this formulation and underscoring the persistent risk of severe bleeding complications even with advanced agents.[29]

B. Peripheral Arterial Occlusion (PAO)

Staphylokinase has also been studied extensively for the treatment of PAO, typically administered via intra-arterial, catheter-directed infusion to maximize local drug concentration and minimize systemic exposure.

• Efficacy and Revascularization: A large study involving 191 patients with PAO demonstrated high efficacy for rSAK. After a mean administration of 12 mg over 14 hours, complete revascularization was achieved in 83% of patients, with partial lysis in another 13%. This led to a high one-year amputation-free survival rate of 84%.[31] Notably, the lysis rate was not significantly different between acute occlusions (≤14 days) and those of longer duration, suggesting a broader window for intervention.[32] Pilot studies in smaller cohorts confirmed these high rates of vessel patency.[22]
• Safety and Complications: While effective, intra-arterial thrombolysis with rSAK was associated with significant safety concerns. The large 191-patient study reported major bleeding in 12% of patients. Most concerning was the occurrence of fatal intracranial hemorrhage in four patients (2.1%). These events occurred predominantly in elderly patients (all >74 years) with severe comorbidities such as hypertension and diabetic arteriopathy, highlighting a high-risk population for this intervention.[22]

C. Venous Thromboembolism (VTE)

More recent clinical development has focused on VTE, particularly with the advent of non-immunogenic SAK variants.

• Deep Vein Thrombosis (DVT): A small feasibility study evaluated catheter-directed infusion of rSAK in six patients with DVT. The treatment was associated with a high frequency of thrombolysis, achieving complete lysis in five patients and partial lysis in one. Minor bleeding occurred in four subjects, and one experienced symptomatic reocclusion. The study concluded that the approach was feasible and warranted larger trials.[36]
• Pulmonary Embolism (PE): The most significant recent advance in the clinical story of staphylokinase comes from the FORPE trial, a multicenter, randomized trial conducted in Russia. This study compared a non-immunogenic variant of staphylokinase (Fortelyzin) against alteplase in 310 patients with massive PE and hemodynamic instability.[24]
• Non-Inferior Efficacy: Fortelyzin, administered as a single 15 mg intravenous bolus, was found to be non-inferior to the standard 100 mg infusion of alteplase. The primary efficacy endpoint, 7-day all-cause mortality, was 2% in the Fortelyzin group versus 3% in the alteplase group.[39]
• Superior Safety Profile: The most striking result of the FORPE trial was the superior safety of the non-immunogenic SAK variant. There were zero cases of hemorrhagic stroke or major bleeding (BARC type 3 or 5) in the Fortelyzin group. In contrast, the alteplase group had five incidences of major bleeding (3-5%), all of which occurred in patients over 60 years old. This finding strongly suggests that the high fibrin-selectivity of staphylokinase translates into a tangible clinical safety benefit, particularly a reduced risk of severe hemorrhage compared to alteplase.[24]

The trajectory of staphylokinase's clinical evaluation reveals a clear narrative. Initial trials in arterial thrombosis successfully established its potent efficacy, often comparable to the gold-standard t-PA, and consistently demonstrated its superior fibrin-sparing properties. However, these same trials invariably uncovered its two primary liabilities: a potent immunogenic response and a persistent, albeit potentially lower, risk of severe bleeding. The recent success of the non-immunogenic variant Fortelyzin in the FORPE trial represents the culmination of these efforts. By addressing the immunogenicity challenge through molecular engineering, this next-generation staphylokinase has delivered on the original promise of the molecule: equivalent thrombolytic efficacy with a markedly improved safety profile, particularly with respect to major bleeding events. This positions non-immunogenic staphylokinase as a highly compelling alternative to current standard-of-care thrombolytics.

Overcoming Clinical Limitations: Safety, Immunogenicity, and Variant Engineering

The journey of staphylokinase from a promising laboratory finding to a viable clinical therapeutic has been defined by the systematic effort to overcome its inherent biological limitations. While its efficacy was established early, its safety profile and, most critically, its immunogenicity presented formidable barriers to widespread adoption.

A. Safety Profile: The Bleeding Conundrum

Despite its high degree of fibrin-specificity, staphylokinase is not devoid of bleeding risk. The process of dissolving a pathological thrombus inherently interferes with hemostasis, and all effective thrombolytic agents carry a risk of hemorrhage. Clinical trials with rSAK, particularly in the treatment of peripheral arterial occlusion, documented major bleeding complications in up to 12% of patients.[32] The most severe of these is intracranial hemorrhage (ICH), which occurred in 2.1% of patients in one large PAO study and was uniformly fatal.[31] These events were often concentrated in elderly patients with multiple comorbidities, defining a population at particularly high risk.[31]

However, the recent FORPE trial, which compared a non-immunogenic SAK variant (Fortelyzin) to alteplase in patients with massive pulmonary embolism, has provided compelling evidence of a superior safety profile for the engineered molecule. In this randomized trial, there were zero instances of major bleeding or hemorrhagic stroke in the Fortelyzin arm, compared to five major bleeding events, including fatal ICH, in the alteplase arm.[24] This suggests that the enhanced fibrin-selectivity of staphylokinase may indeed translate into a clinically meaningful reduction in severe bleeding complications compared to t-PA, a finding that could reposition SAK as a first-line agent if validated in broader populations.

B. The Immunogenicity Challenge: A Barrier to Widespread Use

The most significant obstacle to the clinical development of wild-type staphylokinase was its origin as a bacterial protein, which rendered it highly immunogenic in humans.

• Humoral Immune Response: Virtually all clinical trials involving intravenous administration of wild-type rSAK reported the development of high titers of neutralizing IgG antibodies in the majority of patients (over 73-80%).[10] These antibodies typically appeared with a lag phase of 10-20 days post-treatment and could persist at elevated levels for months to years, effectively precluding the safe and effective re-administration of the drug.[22] This immunogenicity represented a critical flaw for a drug intended for conditions that can recur.
• Cellular Immune Response: The humoral response is driven by a T-cell-dependent mechanism. Staphylokinase acts as a potent T-cell antigen, provoking the proliferation of SAK-specific T-lymphocytes that can remain elevated for over 10 months post-treatment.[45] Detailed epitope mapping studies identified six distinct immunogenic regions within the SAK molecule that are recognized by T-cells. Crucially, several of these T-cell epitopes were found to be promiscuous, capable of being presented by multiple different HLA-DR alleles, which explains why a robust immune response is observed across a broad and diverse patient population.[45]
• Mapping B-Cell Epitopes: To guide engineering efforts, researchers also mapped the B-cell epitopes—the specific sites on the protein surface recognized by antibodies. Using panels of monoclonal antibodies, three non-overlapping, immunodominant epitopes were identified. These epitopes were largely defined by clusters of charged amino acids on the protein's surface, such as Lys35, Glu38, Lys74, Glu75, Arg77, Glu80, and Asp82.[10] This detailed molecular understanding of SAK's antigenicity provided a precise roadmap for its re-engineering.

C. Engineering a Better Thrombolytic: The Rise of SAK Variants

The predictable but problematic immunogenicity of staphylokinase spurred a decades-long, rational drug design effort aimed at creating variants with reduced antigenicity that retained full thrombolytic potency.

• Site-Directed Mutagenesis: The primary strategy involved site-directed mutagenesis, specifically a technique known as "clustered charge-to-alanine scanning".[10] This approach systematically replaced the charged amino acid residues within the identified B-cell epitopes with the small, neutral amino acid alanine, with the goal of disrupting antibody binding without significantly altering the protein's overall structure and function. This led to the creation of several combination mutants, such as:
• SakSTAR.M38: Contained five substitutions (K35A, E38A, K74A, E75A, R77A).
• SakSTAR.M89: Contained five different substitutions (K74A, E75A, R77A, E80A, D82A). These variants successfully demonstrated reduced reactivity with patient antibodies but often came at the cost of reduced specific activity (approximately 50% of wild-type) and lower temperature stability, highlighting the delicate balance between modifying immunogenicity and preserving function.10
• Non-Immunogenic Staphylokinase (Fortelyzin): The culmination of this engineering effort is the non-immunogenic variant known as Fortelyzin, developed by the laboratory of D. Collen and commercialized by SuperGene LLC.[24] This variant incorporates three key amino acid substitutions: Lys74Ala, Glu75Ala, and Arg77Ala.[24] These mutations target one of the most immunodominant epitopes. Clinical studies confirmed the success of this approach, demonstrating that this variant induced over 200-fold lower titers of neutralizing antibodies in patients compared to the wild-type protein. This modification effectively solved the immunogenicity problem while preserving the molecule's high thrombolytic activity and fibrin-selectivity, as evidenced by its clinical success in the FRIDA and FORPE trials in Russia.[24]
• PEGylation: An alternative engineering strategy explored was PEGylation, the covalent attachment of polyethylene glycol (PEG) chains to the protein. This approach aimed to both prolong the drug's circulatory half-life (enabling single-bolus administration) and physically shield antigenic epitopes from the immune system.[30] A PEGylated SAK (PEG-Sak) was tested in the CAPTORS II trial. While it proved feasible for bolus injection, the trial was stopped due to an increased risk of intracranial hemorrhage at higher doses, suggesting that for SAK, PEGylation may create a narrow therapeutic window that compromises its safety advantage.[29]

The development path of staphylokinase is a powerful illustration of how a fundamental biological obstacle can be overcome through rational, structure-guided protein engineering. The initial failure of the wild-type protein was not due to a lack of efficacy but to a predictable immune response. By meticulously mapping the molecular interface between the drug and the immune system and making precise modifications, researchers were able to design a second-generation molecule that retained the therapeutic benefits of the original while eliminating its primary liability. The clinical success of the non-immunogenic Fortelyzin variant is the direct and tangible result of this sophisticated, multi-decade scientific endeavor.

Variant Name	Key Mutations / Modification	Engineering Strategy	Impact on Immunogenicity	Impact on Thrombolytic Activity	Key Clinical Finding / Status
Wild-type rSAK (SakSTAR)	None	Recombinant expression	High; induces neutralizing antibodies in >80% of patients 22	High potency and fibrin-specificity	Efficacy established in AMI and PAO, but immunogenicity prevents re-dosing and widespread use 22
SakSTAR.M38	K35A, E38A, K74A, E75A, R77A	Site-directed mutagenesis (charge-to-alanine)	Reduced reactivity with patient antibodies 10	Reduced to ~50% of wild-type activity 10	Investigational; demonstrated proof-of-concept for reducing immunogenicity 50
SakSTAR.M89	K74A, E75A, R77A, E80A, D82A	Site-directed mutagenesis (charge-to-alanine)	Reduced reactivity with patient antibodies 10	Reduced to ~50% of wild-type activity 10	Investigational; demonstrated proof-of-concept for reducing immunogenicity 50
PEG-Sak	Site-specific covalent attachment of polyethylene glycol (PEG)	PEGylation	Potentially reduced by shielding epitopes; half-life extended	Potency maintained	Feasible for single bolus injection, but associated with increased ICH risk at higher doses (CAPTORS II trial) 29
Fortelyzin (non-immunogenic SAK)	K74A, E75A, R77A	Site-directed mutagenesis (charge-to-alanine)	>200-fold reduction in antibody induction 24	High potency and fibrin-specificity maintained	Approved in Russia for AMI, stroke, and PE; non-inferior to alteplase with superior safety profile in FORPE trial 42

The Dual Role of Staphylokinase in Staphylococcus aureus Pathogenesis

Beyond its therapeutic application, staphylokinase plays a fascinating and complex role in the biology of its native producer, Staphylococcus aureus. It is considered a key virulence factor, yet its contribution to disease is nuanced and context-dependent, reflecting an intricate evolutionary relationship between the pathogen and its human host.

SAK as a Virulence Factor for Invasion

The primary role of staphylokinase in pathogenesis is to facilitate bacterial invasion and tissue penetration.[9]

S. aureus leverages the host's own fibrinolytic system as a weapon. By secreting SAK, the bacterium activates host plasminogen into plasmin. This potent protease then degrades key components of the extracellular matrix and basement membranes, such as fibrin, fibronectin, and laminin.[9] This enzymatic activity allows the bacteria to break through tissue barriers and escape from fibrin clots that the host forms to contain the infection.[59]

This mechanism is clinically relevant. Studies have shown that the ability to produce staphylokinase is significantly more common among S. aureus strains isolated from skin and soft tissue infections compared to strains from other sources.[9] This strong correlation suggests that SAK production provides a selective advantage for the bacterium in establishing these common types of infections.

A Paradoxical Role in Disease Severity and Immune Evasion

While SAK promotes the initial establishment of local infections, its role in the progression to more severe, systemic disease is paradoxical. Evidence suggests that SAK-mediated plasminogen activation does not necessarily promote systemic bacterial dissemination from an established infection site. In fact, in models of abscess formation, the proteolytic activity generated by SAK may actually decrease overall disease severity by promoting the opening and drainage of the abscess, thereby facilitating clearance.[59]

In addition to its role in tissue invasion, staphylokinase also contributes directly to immune evasion. It has been shown to interact with and neutralize α-defensins, which are antimicrobial peptides produced by neutrophils and other cells as a crucial part of the innate immune response.[60] By abrogating the bactericidal effect of these defensins, SAK helps protect the bacteria from being killed by the host's first-line immune defenses.[60]

This dual functionality highlights the sophisticated nature of staphylokinase as a virulence factor. It is a multi-purpose tool that allows S. aureus to navigate different stages of the infection process—using plasminogen activation to breach initial barriers and neutralizing host peptides to survive the immediate immune assault. This complex biological role provides a rich backdrop for understanding its mechanism of action as a therapeutic agent and underscores the intricate co-evolution of pathogens and the host immune system.

Biomanufacturing and Production of Recombinant Staphylokinase

The transition of staphylokinase from a research tool to a potential clinical therapeutic necessitated the development of robust and scalable manufacturing processes. The production of clinical-grade recombinant SAK (rSAK) has faced several bioprocess engineering challenges, the solutions to which have mirrored broader advances in recombinant protein production technology.

A. Expression Systems

The workhorse for rSAK production has overwhelmingly been the bacterium Escherichia coli. Its rapid growth, well-understood genetics, and capacity for high-level protein expression make it an attractive host. Numerous studies have utilized various E. coli strains (e.g., BL21(DE3), TG1) and expression vectors (e.g., pET series) to produce gram-quantities of rSAK.[7] However, other expression systems have also been explored to circumvent issues encountered with

E. coli. These include the gram-positive bacterium Bacillus subtilis, which is capable of secreting proteins directly into the culture medium, and the yeast Pichia pastoris, a eukaryotic host that can perform post-translational modifications, though SAK is non-glycosylated.[63]

B. Industrial-Scale Production Challenges

While high expression levels can be achieved, the large-scale production of rSAK in E. coli presents significant challenges:

• Inclusion Body Formation: The most common and significant hurdle is the tendency for overexpressed rSAK to misfold and aggregate into dense, insoluble intracellular particles known as inclusion bodies.[66] While this protects the protein from host proteases and simplifies initial isolation, it renders the protein biologically inactive.
• Solubilization and Refolding: Recovering active protein from inclusion bodies is a multi-step, often inefficient, and costly process. It requires initial cell lysis, isolation of the inclusion bodies, solubilization using harsh chaotropic denaturants like urea or guanidine hydrochloride, and finally, a carefully controlled refolding process (e.g., gradual removal of the denaturant) to allow the protein to assume its correct three-dimensional structure. This entire downstream process can be difficult to scale and often results in significant loss of active protein.[15]
• Process Instability: Other challenges include the instability of the expression plasmid within the bacterial host during long fermentation runs and the potential for proteolytic degradation of the target protein by host enzymes, both of which can lead to inconsistent and lower-than-expected yields.[65]

C. Bioprocess Engineering Solutions

To overcome these challenges, researchers have developed sophisticated bioprocess engineering strategies for both upstream (fermentation) and downstream (purification) processing.

• Optimized Fermentation: High-density cell cultures are achieved using optimized fermentation strategies, such as fed-batch culture, where nutrients are continuously supplied to the fermentor. Precise control over parameters like pH, dissolved oxygen concentration, and nutrient feed rates is crucial for maximizing cell growth and protein expression.[64]
• Advanced Purification Protocols: The purification of clinical-grade rSAK requires a multi-step chromatographic procedure to achieve the high purity (>97-99%) required for human use. A typical protocol for rSAK recovered from cytosol or solubilized inclusion bodies involves:

1. Ion-Exchange Chromatography: Often using a cation-exchange resin like SP-Sepharose to capture the positively charged SAK protein.[28]
2. Hydrophobic Interaction Chromatography: Using a resin like phenyl-Sepharose to further separate SAK from remaining contaminants based on surface hydrophobicity.[28]
3. Affinity Chromatography: For tagged versions of rSAK (e.g., His-tagged), Ni²⁺-affinity chromatography provides a highly specific and efficient purification step.[71]

• Soluble Expression Systems: A major breakthrough in SAK manufacturing was the development of expression systems designed to produce the protein in its soluble, active form, thereby circumventing the entire inclusion body and refolding problem. One highly successful approach utilizes a "cold-shock" expression vector (e.g., pCOLDI) in E. coli. By inducing protein expression at a low temperature (e.g., 15°C) instead of the standard 37°C, the rate of protein synthesis is slowed, allowing more time for correct folding and preventing aggregation. This strategy has been reported to yield large quantities of soluble, active rSAK, with purified protein yields as high as 913 mg/L of fermentation broth—a significant improvement over previous methods.[66]

The evolution of staphylokinase manufacturing illustrates a critical principle in biopharmaceutical development: process is product. The initial focus on maximizing expression levels in E. coli created significant downstream bottlenecks. The ultimate solution was not merely to optimize the purification of misfolded protein, but to re-engineer the upstream expression process itself to generate a more manufacturable product. The development of cost-effective, scalable processes for producing high-purity, active staphylokinase was as crucial to its clinical viability as the molecular engineering that solved its immunogenicity.

Regulatory Status and Future Directions

A. Global Regulatory Landscape

The regulatory status of staphylokinase varies significantly across different regions, reflecting divergent paths of clinical development and regulatory assessment.

• United States (FDA): To date, no staphylokinase-containing product has been approved for clinical use by the U.S. Food and Drug Administration (FDA). It remains an investigational agent in the United States. While early clinical trials were conducted, and some variants were developed, none have successfully completed the rigorous FDA approval process.[12] Streptokinase, another bacterial thrombolytic, is also no longer commercially available in the U.S..[72]
• European Union (EMA): Similarly, staphylokinase has not received marketing authorisation from the European Medicines Agency (EMA). A search of the EMA's databases reveals no approved medicinal products containing staphylokinase.[53] The only thrombolytic agent approved by both the FDA and EMA for acute ischemic stroke is alteplase.[19]
• Russian Federation: In a notable contrast, a non-immunogenic recombinant variant of staphylokinase, marketed under the brand name Fortelyzin® and developed by the Russian company SuperGene LLC, has achieved regulatory approval and is in clinical use.[18] Fortelyzin® was first registered in Russia for the treatment of ST-segment elevation myocardial infarction (STEMI) in 2012, followed by an approval for acute ischemic stroke in 2020, and most recently for massive pulmonary embolism in 2023.[6]

B. Future Prospects and Conclusion

Staphylokinase stands at a pivotal juncture. After decades of research that saw its initial promise hindered by immunogenicity, the development of non-immunogenic variants has revitalized its therapeutic potential.

The clinical data from Russian trials, particularly the FORPE trial in massive pulmonary embolism, are compelling. The demonstration of non-inferior efficacy to alteplase, combined with a significantly superior safety profile characterized by a lack of major bleeding or hemorrhagic stroke, positions non-immunogenic staphylokinase as a formidable next-generation thrombolytic.[24] The additional advantages of single-bolus administration, which is ideal for emergency settings, and lower production costs due to its bacterial origin and small size, further enhance its attractiveness as a potential global standard of care.[53]

Moreover, the scientific story of staphylokinase may not be over. Recent advanced kinetic analyses have uncovered previously unknown rate-limiting steps in its mechanism of action. These findings suggest that the true catalytic potential of staphylokinase may be up to 1000-fold higher than that of alteplase and that its currently realized efficiency is only a fraction of its theoretical maximum.[53] This opens up new avenues for protein engineering to design future variants with even greater potency, potentially allowing for lower doses and an even wider therapeutic window.

In conclusion, the journey of staphylokinase from a bacterial virulence factor to a clinically approved, highly engineered thrombolytic agent is a testament to the power of persistent, rational drug design. While regulatory approval in Western markets remains a future goal, the compelling clinical evidence from Russia provides a strong impetus for its continued development. Staphylokinase, particularly in its non-immunogenic form, holds the potential to become a safer, more effective, and more accessible thrombolytic agent, offering a new horizon in the treatment of life-threatening thrombotic diseases worldwide.

Works cited

1. STAPHYLOKINASE: A BOON IN MEDICAL SCIENCES – REVIEW, accessed June 17, 2025, https://www.mjpms.in/articles/staphylokinasea-boon-in-medical-sciences-review.pdf
2. Fibrin-Selective Thrombolytic Therapy for Acute Myocardial Infarction | Circulation, accessed June 17, 2025, https://www.ahajournals.org/doi/10.1161/01.cir.93.5.857
3. Bacterial staphylokinase as a promising third-generation drug in the treatment for vascular occlusion | Request PDF - ResearchGate, accessed June 17, 2025, https://www.researchgate.net/publication/336968835_Bacterial_staphylokinase_as_a_promising_third-generation_drug_in_the_treatment_for_vascular_occlusion
4. The evolution of recombinant thrombolytics: Current status and future directions - PMC, accessed June 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5553328/
5. Mechanism of the action of staphylokinase for dissolving the clot.... - ResearchGate, accessed June 17, 2025, https://www.researchgate.net/figure/Mechanism-of-the-action-of-staphylokinase-for-dissolving-the-clot-Fibrin-specific_fig1_336968835
6. Staphylokinase – Knowledge and References - Taylor & Francis, accessed June 17, 2025, https://taylorandfrancis.com/knowledge/Medicine_and_healthcare/Pathology/Staphylokinase/
7. Staphylokinase Enzyme Recombinant | SAK Protein | ProSpec, accessed June 17, 2025, https://www.prospecbio.com/staphylokinase
8. Molecular conversions of recombinant staphylokinase during plasminogen activation in purified systems and in human plasma - PubMed, accessed June 17, 2025, https://pubmed.ncbi.nlm.nih.gov/8259556/
9. Staphylokinase Production by Clinical Staphylococcus aureus Strains - Polish Journal of Microbiology, accessed June 17, 2025, http://www.pjmonline.org/wp-content/uploads/2015/12/vol5622007097.pdf
10. Recombinant Staphylokinase Variants With Altered ..., accessed June 17, 2025, https://www.ahajournals.org/doi/10.1161/01.cir.94.2.197
11. Mechanism of action and thrombolytic potential of staphylokinase, accessed June 17, 2025, https://pubmed.ncbi.nlm.nih.gov/8571666/
12. Computer-aided engineering of staphylokinase toward enhanced affinity and selectivity for plasmin - PMC, accessed June 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8941168/
13. Staphylokinase (Recombinant) - bioWORLD, accessed June 17, 2025, https://www.bio-world.com/recombinant-proteins/staphylokinase-recombinant-p-22060679
14. Anti-stroke biologics: from recombinant proteins to stem cells and organoids - PMC, accessed June 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11732845/
15. (PDF) Staphylokinase Enzyme: An Overview of Structure, Function and Engineered Forms, accessed June 17, 2025, https://www.researchgate.net/publication/323092276_Staphylokinase_Enzyme_An_Overview_of_Structure_Function_and_Engineered_Forms
16. pubmed.ncbi.nlm.nih.gov, accessed June 17, 2025, https://pubmed.ncbi.nlm.nih.gov/8571666/#:~:text=Staphylokinase%20is%20a%20profibrinolytic%20agent,rapidly%20inhibited%20by%20alpha2%2Dantiplasmin.
17. Reprogrammed streptokinases develop fibrin-targeting and dissolve blood clots with more potency than tissue plasminogen activator, accessed June 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3911889/
18. Massive Pulmonary Embolism: Trial of Non-immunogenic Recombinant Staphylokinase VS Alteplase FORPE | Clinical Research Trial Listing - CenterWatch, accessed June 17, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT04688320/massive-pulmonary-embolism-trial-of-non-immunogenic-recombinant-staphylokinase-vs-alteplase-forpe
19. Development and Testing of Thrombolytics in Stroke - :: Journal of Stroke, accessed June 17, 2025, https://www.j-stroke.org/journal/view.php?doi=10.5853/jos.2020.03349
20. New fibrinolytic agents for MI: As effective as current agents, but easier to administer, accessed June 17, 2025, https://www.ccjm.org/content/ccjom/71/1/20.full.pdf
21. Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase | JACC, accessed June 17, 2025, https://www.jacc.org/doi/10.1016/0735-1097%2888%2990158-1
22. Thrombolytic therapy of peripheral arterial occlusion with recombinant staphylokinase - PubMed, accessed June 17, 2025, https://pubmed.ncbi.nlm.nih.gov/7554181/
23. Randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction - Portal de Periódicos da CAPES, accessed June 17, 2025, https://www.periodicos.capes.gov.br/index.php/acervo/buscador.html?task=detalhes&id=W2062224383
24. (PDF) The Safety of Non‐immunogenic Recombinant Staphylokinase in Elderly Patients With Massive Pulmonary Embolism: A Randomized Clinical Trial FORPE - ResearchGate, accessed June 17, 2025, https://www.researchgate.net/publication/391863619_The_Safety_of_Non-immunogenic_Recombinant_Staphylokinase_in_Elderly_Patients_With_Massive_Pulmonary_Embolism_A_Randomized_Clinical_Trial_FORPE
25. Fibrinolysis for Acute Myocardial Infarction - American Heart Association Journals, accessed June 17, 2025, https://www.ahajournals.org/doi/pdf/10.1161/01.cir.103.23.2862
26. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group - PubMed, accessed June 17, 2025, https://pubmed.ncbi.nlm.nih.gov/7554180/
27. A Randomized Trial of Recombinant Staphylokinase Versus Alteplase for Coronary Artery Patency in Acute Myocardial Infarction | Circulation - American Heart Association Journals, accessed June 17, 2025, https://www.ahajournals.org/doi/10.1161/01.cir.92.8.2044
28. High yield production and purification of recombinant staphylokinase for thrombolytic therapy - PubMed, accessed June 17, 2025, https://pubmed.ncbi.nlm.nih.gov/7764434/
29. Collaborative Angiographic Patency Trial of Recombinant Staphylokinase (CAPTORS II) | Request PDF - ResearchGate, accessed June 17, 2025, https://www.researchgate.net/publication/10590617_Collaborative_Angiographic_Patency_Trial_of_Recombinant_Staphylokinase_CAPTORS_II
30. Collaborative Angiographic Patency Trial Of Recombinant Staphylokinase (CAPTORS II). - SummitMD, accessed June 17, 2025, https://www.summitmd.com/html/summit/2004/summit_syllabus_01_detail.php?year=2004&page=5&no_title=22
31. Outcome and One Year Follow-up of Intra-arterial Staphylokinase in 191 Patients with Peripheral Arterial Occlusion - Thieme Connect, accessed June 17, 2025, https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0037-1613889?device=desktop&innerWidth=412&offsetWidth=412
32. Outcome and one year follow-up of intra-arterial staphylokinase in 191 patients with peripheral arterial occlusion - PubMed, accessed June 17, 2025, https://pubmed.ncbi.nlm.nih.gov/10823259/
33. Steven Vanderschueren's research works | Universitair Ziekenhuis Leuven and other places, accessed June 17, 2025, https://www.researchgate.net/scientific-contributions/Steven-Vanderschueren-2120251398
34. Outcome and One Year Follow-up of Intra-arterial ... - Thieme Connect, accessed June 17, 2025, https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0037-1613889.pdf
35. Thrombolytic Therapy of Peripheral Arterial Occlusion With ..., accessed June 17, 2025, https://www.ahajournals.org/doi/10.1161/01.CIR.92.8.2050?doi=10.1161/01.CIR.92.8.2050
36. pubmed.ncbi.nlm.nih.gov, accessed June 17, 2025, https://pubmed.ncbi.nlm.nih.gov/9531032/#:~:text=Thus%20catheter%2Ddirected%20infusion%20of,treatment%20appear%20to%20be%20warranted.
37. Feasibility study of catheter-directed thrombolysis with recombinant ..., accessed June 17, 2025, https://pubmed.ncbi.nlm.nih.gov/9531032/
38. pmc.ncbi.nlm.nih.gov, accessed June 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12086800/#:~:text=The%20FORPE%20trial%20showed%20that,the%20real%E2%80%90world%20clinical%20practice.
39. Non-immunogenic staphylokinase in patients with massive intermediate-high risk pulmonary embolism: protocol of the FORPE-2 multicenter, double-blind, randomized, placebo-controlled trial - ResearchGate, accessed June 17, 2025, https://www.researchgate.net/publication/389903222_Non-immunogenic_staphylokinase_in_patients_with_massive_intermediate-high_risk_pulmonary_embolism_protocol_of_the_FORPE-2_multicenter_double-blind_randomized_placebo-controlled_trial
40. The Safety of Non‐immunogenic Recombinant Staphylokinase in Elderly Patients With Massive Pulmonary Embolism: A Randomized Clinical Trial FORPE - PMC - PubMed Central, accessed June 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12086800/
41. The Safety of Non-immunogenic Recombinant Staphylokinase in Elderly Patients With Massive Pulmonary Embolism: A Randomized Clinical Trial FORPE - PubMed, accessed June 17, 2025, https://pubmed.ncbi.nlm.nih.gov/40391253/
42. Non-immunogenic staphylokinase — a thrombolytic agent in the ..., accessed June 17, 2025, https://russjcardiol.elpub.ru/jour/article/view/6157?locale=en_US
43. Recombinant staphylokinase(Supergene Co. Ltd.) - Drug Targets, Indications, Patents, accessed June 17, 2025, https://synapse.patsnap.com/drug/42a1108cf3dd4b4cafb344c89ac1ce51
44. On the Immunogenicity of Recombinant Staphylokinase in Patients and in Animal Models, accessed June 17, 2025, https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0038-1648856
45. Staphylokinase-Specific Cell-Mediated Immunity in Humans1 - AAI Journals, accessed June 17, 2025, https://journals.aai.org/jimmunol/article/168/1/155/70632/Staphylokinase-Specific-Cell-Mediated-Immunity-in
46. Crystal structure of a staphylokinase variant: A model for reduced antigenicity | Request PDF, accessed June 17, 2025, https://www.researchgate.net/publication/11505989_Crystal_structure_of_a_staphylokinase_variant_A_model_for_reduced_antigenicity
47. High Resolution Mapping of the B Cell Epitopes of Staphylokinase in Humans Using Negative Selection of a Phage-Displayed Antigen Library1 - AAI Journals, accessed June 17, 2025, https://journals.aai.org/jimmunol/article/161/6/3161/31418/High-Resolution-Mapping-of-the-B-Cell-Epitopes-of
48. Recombinant Staphylokinase Variants With Altered Immunoreactivity | Circulation, accessed June 17, 2025, https://www.ahajournals.org/doi/10.1161/01.CIR.94.2.197?doi=10.1161/01.CIR.94.2.197
49. Recombinant staphylokinase variants with altered immunoreactivity. I: Construction and characterization - PubMed, accessed June 17, 2025, https://pubmed.ncbi.nlm.nih.gov/8674179/
50. Recombinant Staphylokinase Variants With Altered Immunoreactivity: II: Thrombolytic Properties and Antibody Induction - American Heart Association Journals, accessed June 17, 2025, https://www.ahajournals.org/doi/10.1161/01.cir.94.2.207
51. Recombinant Staphylokinase Variants With Altered Immunoreactivity | Circulation, accessed June 17, 2025, https://www.ahajournals.org/doi/10.1161/01.cir.95.2.463?doi=10.1161/01.CIR.95.2.463
52. Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial - PubMed, accessed June 17, 2025, https://pubmed.ncbi.nlm.nih.gov/34418399/
53. Hidden Potential of Highly Efficient and Widely Accessible Thrombolytic Staphylokinase | Stroke - American Heart Association Journals, accessed June 17, 2025, https://www.ahajournals.org/doi/10.1161/STROKEAHA.122.040219
54. (PDF) Hidden Potential of Highly Efficient and Widely Accessible Thrombolytic Staphylokinase - ResearchGate, accessed June 17, 2025, https://www.researchgate.net/publication/363153176_Hidden_Potential_of_Highly_Efficient_and_Widely_Accessible_Thrombolytic_Staphylokinase
55. Improving the therapeutic potential of staphylokinase, a potent thrombolytic agent - PRISM, accessed June 17, 2025, https://ucalgary.scholaris.ca/items/19f377e0-11d2-42b3-9a6a-601a381f29f1
56. Pharmacokinetic and thrombolytic properties of cysteine-linked polyethylene glycol derivatives of staphylokinase | Blood | American Society of Hematology, accessed June 17, 2025, https://ashpublications.org/blood/article/95/3/936/138622/Pharmacokinetic-and-thrombolytic-properties-of
57. Staphylokinase production by clinical Staphylococcus aureus strains | Request PDF, accessed June 17, 2025, https://www.researchgate.net/publication/6187424_Staphylokinase_production_by_clinical_Staphylococcus_aureus_strains
58. Staphylokinase production by clinical Staphylococcus aureus strains - PubMed, accessed June 17, 2025, https://pubmed.ncbi.nlm.nih.gov/17650679/
59. Staphylokinase Promotes the Establishment of Staphylococcus ..., accessed June 17, 2025, https://academic.oup.com/jid/article/208/6/990/834507
60. Staphylococcus aureus Resists Human Defensins by Production of Staphylokinase, a Novel Bacterial Evasion Mechanism1 - AAI Journals, accessed June 17, 2025, https://journals.aai.org/jimmunol/article/172/2/1169/71722/Staphylococcus-aureus-Resists-Human-Defensins-by
61. High yielding recombinant Staphylokinase in bacterial expression system--cloning, expression, purification and activity studies | Request PDF - ResearchGate, accessed June 17, 2025, https://www.researchgate.net/publication/23465416_High_yielding_recombinant_Staphylokinase_in_bacterial_expression_system--cloning_expression_purification_and_activity_studies
62. (PDF) Over Expression of Recombinant Staphylokinase and Reduction of Inclusion Bodies Using IPTG as Inducer in E. coli BL21 DE3 - ResearchGate, accessed June 17, 2025, https://www.researchgate.net/publication/379079096_Over_Expression_of_Recombinant_Staphylokinase_and_Reduction_of_Inclusion_Bodies_Using_IPTG_as_Inducer_in_E_coli_BL21_DE3
63. Cloning, high-level expression, purification and characterization of a staphylokinase variant, SakφC, from Staphylococcus - African Journals Online, accessed June 17, 2025, https://www.ajol.info/index.php/ajb/article/view/101740/91788
64. Optimization of Staphylokinase Production in Bacillus subtilis Using Inducible and Constitutive Promoters - Korea Science, accessed June 17, 2025, https://www.koreascience.kr/article/JAKO200111920723914.page
65. High-level secretory production of intact, biologically active staphylokinase from Bacillus subtilis - PubMed, accessed June 17, 2025, https://pubmed.ncbi.nlm.nih.gov/10099516/
66. Large scale production of soluble recombinant staphylokinase ..., accessed June 17, 2025, https://www.researchgate.net/publication/288787370_Large_scale_production_of_soluble_recombinant_staphylokinase_variant_from_cold_shock_expression_system_using_IPTG_inducible_E_coli_BL21DE3
67. Production of Bioactive Recombinant Reteplase by Virus-Based Transient Expression System in Nicotiana benthamiana - Frontiers, accessed June 17, 2025, https://www.frontiersin.org/journals/plant-science/articles/10.3389/fpls.2019.01225/full
68. Production of Thrombolytic and Fibrinolytic Proteases: Current Advances and Future Prospective | Request PDF - ResearchGate, accessed June 17, 2025, https://www.researchgate.net/publication/348712218_Production_of_Thrombolytic_and_Fibrinolytic_Proteases_Current_Advances_and_Future_Prospective
69. Biotechnological Advancements in Streptokinase Production, accessed June 17, 2025, https://www.humapub.com/admin/alljournals/gdddr/papers/XjIaJq2nKh.pdf
70. Optimization of Staphylokinase Production in Bacillus subtilis Using Inducible and Constitutive Promoters - CiteSeerX, accessed June 17, 2025, https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=1fc05269bfba8bd4c654c0b453ecf843ad739c73
71. Novel preparation protocol for the expression and purification of recombinant staphylokinase - PubMed, accessed June 17, 2025, https://pubmed.ncbi.nlm.nih.gov/17967161/
72. Streptokinase - Wikipedia, accessed June 17, 2025, https://en.wikipedia.org/wiki/Streptokinase
73. History of Thrombolytics| Strokeforum - Boehringer Ingelheim, accessed June 17, 2025, https://pro.boehringer-ingelheim.com/strokeforum/thrombolysis/history-of-thrombolytics
74. Polyethylene Glycol–Derivatized Cysteine-Substitution Variants of Recombinant Staphylokinase for Single-Bolus Treatment of Acute Myocardial Infarction - American Heart Association Journals, accessed June 17, 2025, https://www.ahajournals.org/doi/10.1161/01.cir.102.15.1766
75. Hidden Potential of Highly Efficient and Widely Accessible Thrombolytic Staphylokinase | Stroke, accessed June 17, 2025, https://www.ahajournals.org/doi/pdf/10.1161/STROKEAHA.122.040219
76. Marketing authorisation | European Medicines Agency (EMA), accessed June 17, 2025, https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation
77. Post-authorisation | European Medicines Agency (EMA), accessed June 17, 2025, https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation
78. Recombinant staphylokinase - Supergene - AdisInsight - Springer, accessed June 17, 2025, https://adisinsight.springer.com/drugs/800041737
79. Hidden Potential of Highly Efficient and Widely Accessible Thrombolytic Staphylokinase, accessed June 17, 2025, https://pubmed.ncbi.nlm.nih.gov/36039755/